Home Stock

Stock Research: NeoGenomics

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

NeoGenomics

NAQ:NEO US64049M2098
71
  • Value
    28
  • Growth
    53
  • Safety
    Safety
    62
  • Combined
    36
  • Sentiment
    83
  • 360° View
    360° View
    71
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. It offers comprehensive oncology-focused testing menus and services including clinical cancer testing, molecular and NGS testing, clinical trials and research, and oncology data solutions. The company operates laboratories across the United States and in Cambridge, United Kingdom. In the last fiscal year, the company had a market cap of $900 million, profits of $290 million, revenue of $661 million, and 2200 employees.

more

ANALYSIS: With an Obermatt 360° View of 71 (better than 71% compared with alternatives), overall professional sentiment and financial characteristics for the stock NeoGenomics are above average. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for NeoGenomics. The consolidated Growth Rank has a good rank of 53, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 53% of competitors in the same industry. The consolidated Safety Rank at 62 means that the company has a financing structure that is safer than 62% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 83, which means that professional investors are more optimistic about the stock than for 83% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 28, meaning that the share price of NeoGenomics is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 72% of alternative stocks in the same industry. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Refinancing
Country USA
Industry Health Care Services
Size Medium
Website neogenomics.com
Index
NASDAQ
NeoGenomics stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 9-Apr-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
28 27 37 51
Growth
53 63 91 9
Safety
Safety
62 46 28 60
Sentiment
83 41 84 59
360° View
360° View
71 33 75 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
23 75 74 74
Opinions Change
50 40 50 50
Pro Holdings
n/a 13 73 67
Market Pulse
81 38 52 18
Sentiment
83 41 84 59
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
28 27 37 51
Growth
53 63 91 9
Safety Safety
62 46 28 60
Combined
36 38 61 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
44 45 41 64
Price vs. Earnings (P/E)
10 15 53 20
Price vs. Book (P/B)
77 61 54 68
Dividend Yield
1 1 1 1
Value
28 27 37 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
59 78 50 45
Profit Growth
27 84 98 4
Capital Growth
73 30 37 76
Stock Returns
46 35 95 25
Growth
53 63 91 9
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
64 46 36 46
Refinancing
91 54 48 65
Liquidity
11 26 22 37
Safety Safety
62 46 28 60

Similar Stocks

Discover high‑ranked alternatives to NeoGenomics and broaden your portfolio horizons.

Micron

NSQ:MU
Country: USA
Industry: Semiconductors
Size: XX-Large
Full Stock Analysis

Salesforce

NYQ:CRM
Country: USA
Industry: Application Software
Size: XX-Large
Full Stock Analysis

Microsoft

NSQ:MSFT
Country: USA
Industry: Systems Software
Size: XX-Large
Full Stock Analysis

ResMed

NYQ:RMD
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This stock offers a high growth opportunity with safe financing and positive sentiment. It is typically expensive (low Value Rank), as investors pay a premium for high performance. It is for growth-focused investors comfortable paying a premium for a stock with strong future momentum.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews